Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Ocular Therapeutix Inc (NASDAQ: OCUL) closed at $11.87 down -3.50% from its previous closing price of $12.3. In other words, the price has decreased by -$3.50 from its previous closing price. On the day, 0.9 million shares were traded. OCUL stock price reached its highest trading level at $12.358 during the session, while it also had its lowest trading level at $11.835.
Ratios:
For a deeper understanding of Ocular Therapeutix Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.02 and its Current Ratio is at 10.09. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.24.
On March 18, 2025, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $17. On March 11, 2025, Needham started tracking the stock assigning a Buy rating and target price of $15.Needham initiated its Buy rating on March 11, 2025, with a $15 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 25 ’25 when PRAVIN DUGEL bought 21,494 shares for $12.04 per share.
SANJAY NAYAK bought 1,885 shares of OCUL for $22,702 on Aug 25 ’25. On Aug 25 ’25, another insider, JEFFREY S. HEIER, who serves as the Officer of the company, bought 3,063 shares for $12.04 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 2065320704 and an Enterprise Value of 1751128320. For the stock, the TTM Price-to-Sale (P/S) ratio is 36.45 while its Price-to-Book (P/B) ratio in mrq is 6.71. Its current Enterprise Value per Revenue stands at 30.904 whereas that against EBITDA is -7.379.
Stock Price History:
The Beta on a monthly basis for OCUL is 1.50, which has changed by 0.31305313 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, OCUL has reached a high of $12.91, while it has fallen to a 52-week low of $5.78. The 50-Day Moving Average of the stock is 8.15%, while the 200-Day Moving Average is calculated to be 34.65%.
Shares Statistics:
For the past three months, OCUL has traded an average of 2.38M shares per day and 1805710 over the past ten days. A total of 172.93M shares are outstanding, with a floating share count of 145.41M. Insiders hold about 16.43% of the company’s shares, while institutions hold 79.32% stake in the company. Shares short for OCUL as of 1753920000 were 12834007 with a Short Ratio of 5.40, compared to 1751241600 on 14173873. Therefore, it implies a Short% of Shares Outstanding of 12834007 and a Short% of Float of 7.4499995.
Earnings Estimates
The current market rating for Ocular Therapeutix Inc (OCUL) reflects the collective analysis of 4.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.33 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.29 and -$1.62 for the fiscal current year, implying an average EPS of -$1.49. EPS for the following year is -$1.37, with 4.0 analysts recommending between -$1.25 and -$1.59.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $14.39M this quarter.It ranges from a high estimate of $19M to a low estimate of $12.56M. As of the current estimate, Ocular Therapeutix Inc’s year-ago sales were $15.43MFor the next quarter, 11 analysts are estimating revenue of $16.13M. There is a high estimate of $24.6M for the next quarter, whereas the lowest estimate is $13.5M.
A total of 11 analysts have provided revenue estimates for OCUL’s current fiscal year. The highest revenue estimate was $67.8M, while the lowest revenue estimate was $50.3M, resulting in an average revenue estimate of $54.69M. In the same quarter a year ago, actual revenue was $63.72MBased on 11 analysts’ estimates, the company’s revenue will be $65.93M in the next fiscal year. The high estimate is $82.9M and the low estimate is $52.3M.
